ppcian

"CAT is a strong “picks and shovels” AI/data-center beneficiary because it powers AI data centers with record backlog in power-generation capabilities, and my upside case is validated by a move from ~$86 (2013) to ~$889 now with a ~7% yield on cost."

"CARR is a dividend-growth way to play AI cooling because it has a long track record since its 2020 UTX spin-off, and management is delivering AI data-center order momentum with reported orders up ~500% alongside a strong dividend CAGR."

"SOLS looks like an attractive hidden-value dividend-growth candidate where growth catalysts (AI/data centers, nuclear-adjacent end markets, and semiconductor/materials expansion) plus a balance sheet with only ~$2B long-term debt create room for upside, even though the stock is expensive and the dividend is just starting."

"META has long-term dividend-growth potential, but I treat it as a “future” rather than current dividend compounder since the dividend has not increased for a while and I’m cautious about projecting wishes too far forward."

"KO looks like a high-quality dividend compounder again, with Q/Q results cited as revenue up 12% YoY (10% organic), operating margin expanding to 35% from 32.9%, and adjusted EPS up 18% as it gains market share."

"SBUX is on a credible turnaround path with accelerating growth (Q2 same-store sales +6.2%, net revenue +9% or +8% constant currency, EPS up 32% GAAP / 22% non-GAAP) and improving fundamentals from Brian Niccol’s plan, despite a rising effective tax rate that should be monitored."

"KMB remains a dividend-safe buy at roughly a 5% starting yield because results are described as holding the line (organic net sales growth +2.5%, adjusted EPS from continuing operations essentially flat at about -1.2% YoY), with the Ken View acquisition framed as upside while the dividend is expected to be maintained."

"PM is a contrarian dividend compounder despite bearish hype, with the dividend growth story supported by management’s fundamentals showing net revenue up 9.1% (2.7% organic), adjusted diluted EPS up 5.3% in constant currency, and a 2026 forecast calling for 5–7% organic revenue growth and 7–9% operating income growth."

"SO is a value-based dividend winner because the upfront yield and durability of the utility model helped him ride through earlier power-plant concerns, and the company’s dividend increases continue to validate the investment thesis."

"SCHD is my preferred dividend-value approach in 2026 because the rules-based quarterly rebalancing and March reconstitutions systematically tilt toward dividend growth with a value-like starting yield, while the ETF structure helps avoid realizing capital gains consequences for holders so the value build compounds over time."

"JNJ is executing well operationally and is fairly valued at ~19–20x forward PE, but its 3.1% dividend hike was conservative versus its fundamentals and five‑year dividend CAGR (~4.8%), leaving me disappointed even as I keep it as a core 10% position."

"PG faces margin pressure from high input costs and slower top‑line/EPS growth (net sales ~+2%, core EPS ~+4%), so its 3% dividend increase — leaving a ~62.6% payout ratio — was prudent and consistent with the slower growth outlook."

"Kenvue looks like a lower‑quality, slow‑decay business to me — Q4 showed momentum but full‑year organic sales and adjusted EPS declined, the balance sheet has heavy goodwill/intangibles and a ~72% payout at a 4.8% yield, so I view it less favorably than Kimberly‑Clark."

"Clorox is a modest buy for me and a useful comp — trading near a ~17x PE with a tidy balance sheet and a ~4.7% yield, so I hold a small position and use it as a benchmark for where a combined Kimberly‑Clark/Kenvue multiple might reasonably sit."